What were the key drivers of Neuren Pharmaceuticals (ASX:NEU) Q1 2026 growth?

Growth was primarily driven by record net sales of DAYBUE, which reached US$101 million, a 20% increase over Q1 2025. A significant factor was the successful limited launch of DAYBUE STIX, a new powder formulation that saw immediate uptake with over 250 prescriptions. This performance resulted in Q1 royalty income for Neuren of US$10.4 million, up 23% year-on-year.

How did Neuren Pharmaceuticals (ASX:NEU) perform compared to previous years?

The Q1 2026 results represent the highest year-on-year growth for the DAYBUE therapy since the third quarter of 2024. The 20% sales increase and 23% royalty income boost signal a return to accelerating momentum after a more stabilised period.

What is the current market penetration for DAYBUE in the United States?

Market penetration is currently uneven, with approximately 60% uptake in specialist Centres of Excellence (COEs) but only 28% in the broader community. CEO Jon Pilcher identified this gap as a major "upside" opportunity for the company.

What is the 2026 financial guidance for Neuren Pharmaceuticals (ASX:NEU)?

Neuren’s partner, Acadia Pharmaceuticals, has reaffirmed full-year 2026 net sales guidance of US$460–490 million for DAYBUE. For Neuren investors, this translates to an implied annual royalty income of approximately A$70–77 million (based on current exchange rate estimates).

What are the main bull and bear points for Neuren Pharmaceuticals (ASX:NEU) after this update?

The bull case rests on the successful launch of the STIX formulation and the high (80%+) carer satisfaction, which could drive higher long-term adherence. The bear case involves the relatively low 28% penetration in the broader community, which may be harder to capture than the concentrated specialist market.

Neuren shares rise on record DAYBUE sales growth

Written by Heidi Cuthbert Published May. 7 2026Last Updated May. 7 2026

Neuren Pharmaceuticals (ASX:NEU) reported a start to the 2026 financial year, underpinned by record net sales of its flagship Rett syndrome treatment, DAYBUE (trofinetide).

During the first quarter, net sales reached US$101 million, marking a 20% increase compared to the same period in 2025.

The performance represents the highest year-on-year growth for the therapy since late 2024.

Neuren earned Q1 royalty income of US$10.4 million, up 23% from the previous year.

A driver of the momentum was the limited US launch of DAYBUE STIX, a new powder formulation.

The product saw immediate uptake with over 250 prescriptions written and a carer satisfaction rate exceeding 80%.

CEO Jon Pilcher highlighted the immense growth potential remaining in the American market, noting that while penetration has reached 60% in specialist centres of excellence, it sits at only 28% in the broader community.

Looking ahead, Neuren’s partner, Acadia Pharmaceuticals, reaffirmed its full-year 2026 sales guidance of US$460–490 million.

The forecast implies annual royalty income for Neuren of up to $77 million.

Beyond the US, the company is accelerating international clinical trials, with topline results for the Japanese trofinetide trial now expected between September and November.

The financial stability is further bolstered by recent Delphi expert consensus, which officially recommended DAYBUE as part of the standard of care for patients with Rett syndrome.

At the time of reporting, Neuren Pharmaceuticals’ share price was $12.77.